{"contacts": [{"terms": [{"accession": "MS:1000586", "name": "contact name", "value": "Eric Fischer"}, {"accession": "MS:1000589", "name": "contact email", "value": "eric_fischer@dfci.harvard.edu"}, {"accession": "MS:1000590", "name": "contact affiliation", "value": "Dana-Farber Cancer Institute"}, {"accession": "MS:1002037", "name": "dataset submitter"}]}, {"terms": [{"accession": "MS:1002332", "name": "lab head"}, {"accession": "MS:1000586", "name": "contact name", "value": "Eric S. Fischer"}, {"accession": "MS:1000589", "name": "contact email", "value": "eric_fischer@dfci.harvard.edu"}, {"accession": "MS:1000590", "name": "contact affiliation", "value": "Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA"}]}], "datasetFiles": [{"accession": "PRIDE:0000404", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/01/PXD010568/esf_1051.raw"}, {"accession": "PRIDE:0000404", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/01/PXD010568/esf_1052.raw"}, {"accession": "PRIDE:0000404", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/01/PXD010568/esf_1053.raw"}, {"accession": "PRIDE:0000404", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/01/PXD010568/esf_1054.raw"}, {"accession": "PRIDE:0000404", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/01/PXD010568/esf_1055.raw"}, {"accession": "PRIDE:0000404", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/01/PXD010568/esf_1056.raw"}, {"accession": "PRIDE:0000404", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/01/PXD010568/esf_1057.raw"}, {"accession": "PRIDE:0000404", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/01/PXD010568/esf_1058.raw"}, {"accession": "PRIDE:0000404", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/01/PXD010568/esf_1059.raw"}, {"accession": "PRIDE:0000404", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/01/PXD010568/esf_1060.raw"}, {"accession": "PRIDE:0000404", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/01/PXD010568/esf_1061.raw"}, {"accession": "PRIDE:0000404", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/01/PXD010568/esf_1062.raw"}, {"accession": "PRIDE:0000404", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/01/PXD010568/esf_1063.raw"}, {"accession": "PRIDE:0000404", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/01/PXD010568/esf_1064.raw"}, {"accession": "PRIDE:0000404", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/01/PXD010568/esf_1065.raw"}, {"accession": "PRIDE:0000404", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/01/PXD010568/esf_1066.raw"}, {"accession": "PRIDE:0000404", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/01/PXD010568/esf_1067.raw"}, {"accession": "PRIDE:0000404", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/01/PXD010568/esf_1068.raw"}, {"accession": "PRIDE:0000404", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/01/PXD010568/esf_1069.raw"}, {"accession": "PRIDE:0000404", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/01/PXD010568/esf_1070.raw"}, {"accession": "PRIDE:0000404", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/01/PXD010568/esf_1071.raw"}, {"accession": "PRIDE:0000404", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/01/PXD010568/esf_1072.raw"}, {"accession": "PRIDE:0000404", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/01/PXD010568/esf_1073.raw"}, {"accession": "PRIDE:0000404", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/01/PXD010568/esf_1074.raw"}, {"accession": "PRIDE:0000408", "name": "Search engine output file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/01/PXD010568/wp-esf_055_f24_20180724_4manu.pep.xml"}], "description": "The covalent Bruton\u2019s Tyrosine Kinase (BTK) inhibitor ibrutinib is highly efficacious against multiple B-cell malignancies.  However, it also has off-target effects and multiple mechanisms of resistance, including the C481S mutation. We hypothesized that small molecule-induced BTK degradation might be able to overcome some of the limitations of traditional enzymatic inhibitors. Here, we demonstrate that BTK degradation results in more durable suppression of signaling and proliferation in cancer cells than BTK inhibition and that BTK degraders are able to efficiently degrade BTK C481S. Moreover, we generated DD-03-171, an optimized lead compound that exhibits enhanced anti-proliferative effects on mantle cell lymphoma (MCL) cells in vitro as well as efficacy in a patient-derived xenograft model of MCL. These data suggest that targeted BTK degradation is an effective therapeutic approach in treating MCL and overcoming ibrutinib resistance, thereby addressing a major unmet need in the treatment of MCL and other B-cell lymphomas.", "fullDatasetLinks": [{"accession": "PRIDE:0000411", "name": "Dataset FTP location", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/01/PXD010568"}, {"accession": "MS:1001930", "name": "PRIDE project URI", "value": "http://www.ebi.ac.uk/pride/archive/projects/PXD010568"}], "identifiers": [{"accession": "MS:1001919", "name": "ProteomeXchange accession number", "value": "PXD010568"}], "instruments": [{"accession": "MS:1002732", "name": "Orbitrap Fusion Lumos"}], "keywords": [{"accession": "MS:1001925", "name": "submitter keyword", "value": "BTK, IMiDs, PROTAC , ubiquitin, cullin, crl4"}, {"accession": "MS:1001926", "name": "curator keyword", "value": "Biomedical"}], "modifications": [{"accession": "MOD:01720", "name": "TMT6plex-126 reporter+balance reagent acylated residue"}, {"accession": "MOD:00397", "name": "iodoacetamide derivatized residue"}], "publications": [{"terms": [{"accession": "MS:1000879", "name": "PubMed identifier", "value": "30545835"}, {"accession": "PRIDE:0000400", "name": "Reference", "value": "Dobrovolsky D, Wang ES, Morrow S, Leahy C, Faust T, Nowak RP, Donovan KA, Yang G, Li Z, Fischer ES, Treon SP, Weinstock DM, Gray NS. Bruton's Tyrosine Kinase degradation as a therapeutic strategy for cancer. Blood. 2018"}]}], "species": [{"terms": [{"accession": "MS:1001469", "name": "taxonomy: scientific name", "value": "Homo sapiens (Human)"}, {"accession": "MS:1001467", "name": "taxonomy: NCBI TaxID", "value": "9606"}]}], "title": "Bruton\u2019s Tyrosine Kinase Degradation as a Therapeutic Strategy for Cancer"}